EA201171388A1 - Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида - Google Patents

Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида

Info

Publication number
EA201171388A1
EA201171388A1 EA201171388A EA201171388A EA201171388A1 EA 201171388 A1 EA201171388 A1 EA 201171388A1 EA 201171388 A EA201171388 A EA 201171388A EA 201171388 A EA201171388 A EA 201171388A EA 201171388 A1 EA201171388 A1 EA 201171388A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protofibrillary
humanized antibodies
antibodies specific
amyloid peptide
beta amyloid
Prior art date
Application number
EA201171388A
Other languages
English (en)
Other versions
EA028357B1 (ru
Inventor
Николя Борен
Франсис БЛАНШ
Беатрис Камерон
Марк Дюшен
Венсан Миколь
Суад Нэми
Лоран Прадье
И Ши
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41591699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201171388(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи filed Critical Санофи
Publication of EA201171388A1 publication Critical patent/EA201171388A1/ru
Publication of EA028357B1 publication Critical patent/EA028357B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретение относится к гуманизированным антителам, специфичным к протофибриллярной форме бета-амилоидного пептида, а также к применению указанных антител в области болезни Альцгеймера.
EA201171388A 2009-05-12 2010-05-11 Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида EA028357B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0953133A FR2945538B1 (fr) 2009-05-12 2009-05-12 Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
PCT/FR2010/050915 WO2010130946A1 (fr) 2009-05-12 2010-05-11 Anticorps humanises spécifiques de la forme protofibrillaire du peptide béta-amyloide

Publications (2)

Publication Number Publication Date
EA201171388A1 true EA201171388A1 (ru) 2012-05-30
EA028357B1 EA028357B1 (ru) 2017-11-30

Family

ID=41591699

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171388A EA028357B1 (ru) 2009-05-12 2010-05-11 Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида

Country Status (42)

Country Link
US (4) US8614299B2 (ru)
EP (3) EP2430049B1 (ru)
JP (2) JP2012526541A (ru)
KR (1) KR101783058B1 (ru)
CN (1) CN102459336B (ru)
AR (1) AR076670A1 (ru)
AU (1) AU2010247215B2 (ru)
BR (1) BRPI1012853B1 (ru)
CA (1) CA2761665A1 (ru)
CL (1) CL2011002831A1 (ru)
CO (1) CO6460745A2 (ru)
CR (1) CR20110585A (ru)
CY (2) CY1116842T1 (ru)
DK (2) DK2430049T3 (ru)
EA (1) EA028357B1 (ru)
EC (1) ECSP11011452A (ru)
ES (2) ES2664409T3 (ru)
FR (1) FR2945538B1 (ru)
GT (1) GT201100283A (ru)
HK (1) HK1167152A1 (ru)
HR (3) HRP20150776T1 (ru)
HU (1) HUE036737T2 (ru)
IL (1) IL216237B (ru)
LT (1) LT2977385T (ru)
MA (1) MA33350B1 (ru)
MX (1) MX2011012060A (ru)
MY (1) MY159398A (ru)
NI (1) NI201100195A (ru)
NZ (1) NZ596540A (ru)
PE (1) PE20120906A1 (ru)
PL (2) PL2430049T3 (ru)
PT (2) PT2977385T (ru)
RS (1) RS54122B1 (ru)
SG (1) SG176155A1 (ru)
SI (2) SI2430049T1 (ru)
SV (1) SV2011004058A (ru)
TN (1) TN2011000571A1 (ru)
TW (2) TWI542360B (ru)
UA (1) UA107574C2 (ru)
UY (1) UY32633A (ru)
WO (1) WO2010130946A1 (ru)
ZA (1) ZA201108301B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705582A1 (en) 2007-11-16 2009-05-22 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
JP2013159596A (ja) * 2012-02-08 2013-08-19 Nihon Univ β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
JP6669749B2 (ja) 2014-08-08 2020-03-18 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
RS62546B1 (sr) 2015-04-07 2021-12-31 Alector Llc Antitela protiv sortilina i postupci za njihovu upotrebu
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
EP3307771A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
EP3325506A1 (en) 2015-07-21 2018-05-30 BioArctic AB Method for treatment of traumatic brain injury targeting aggregated peptides
CN108137702B (zh) 2015-08-28 2023-01-06 艾利妥 抗siglec-7抗体及其使用方法
KR20180068999A (ko) 2015-10-06 2018-06-22 알렉터 엘엘씨 항-trem2 항체 및 그의 사용방법
US10800844B2 (en) 2015-10-29 2020-10-13 Alector Llc Anti-Siglec-9 antibodies and methods of use thereof
US11472877B2 (en) 2016-03-04 2022-10-18 Alector Llc Anti-TREM1 antibodies and methods of use thereof
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
EP3354278A1 (en) * 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
JP7299160B2 (ja) 2017-08-03 2023-06-27 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
CR20190485A (es) 2017-08-03 2020-02-10 Alector Llc Anticuerpos anti-trem2 y métodos para utilizarlos
MA52753A (fr) 2018-05-25 2021-04-21 Alector Llc Anticorps anti-sirpa et leurs procédés d'utilisation
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
BR112020024919A2 (pt) 2018-06-08 2021-03-09 Alector Llc Anticorpos, ácido nucleico, vetor, célula hospedeira, métodos de produção de um anticorpo e de prevenção, redução do risco ou tratamento de câncer e composição farmacêutica
HUE061841T2 (hu) 2018-07-13 2023-08-28 Alector Llc Anti-sortilin antitestek és felhasználásuk módszerei
EP3830123A1 (en) 2018-07-27 2021-06-09 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
WO2020047374A1 (en) 2018-08-31 2020-03-05 Alector Llc Anti-cd33 antibodies and methods of use thereof
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
TW202110878A (zh) 2019-05-16 2021-03-16 法商賽諾菲公司 在神經系統中表現抗原結合蛋白
KR20220032568A (ko) 2019-06-25 2022-03-15 길리애드 사이언시즈, 인코포레이티드 Flt3l-fc 융합 단백질 및 사용 방법
WO2021035033A1 (en) * 2019-08-20 2021-02-25 The Curators Of The University Of Missouri Amyloid-beta antibodies
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
BR112022011337A2 (pt) 2019-12-12 2022-08-23 Alector Llc Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo
EP4204092A1 (en) 2020-08-25 2023-07-05 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting hiv and methods of use
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
AU2001291096A1 (en) * 2000-09-15 2002-03-26 Coley Pharmaceutical Gmbh Process for high throughput screening of CpG-based immuno-agonist/antagonist
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US7919086B2 (en) * 2004-07-09 2011-04-05 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
EP2298807A3 (en) * 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
CA2582683A1 (en) * 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian eag1 ion channel protein
EP1841455A1 (en) * 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
WO2007108755A1 (en) * 2006-03-22 2007-09-27 Gyros Patent Ab Plex method
KR101413615B1 (ko) * 2006-03-23 2014-07-18 바이오악틱 뉴로사이언스 에이비 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도
CN101622275B (zh) * 2007-01-05 2013-11-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
CA2676049C (en) * 2007-03-01 2018-04-10 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
LT2195023T (lt) 2007-08-29 2018-06-25 Sanofi Humanizuoti anti-cxcr5 antikūnai, jų dariniai ir jų panaudojimas
CA2705582A1 (en) * 2007-11-16 2009-05-22 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
ES2633965T3 (es) * 2008-07-08 2017-09-26 Geneuro Sa Uso terapéutico de ligando específico en enfermedades asociadas a MSRV
DK2406288T3 (en) * 2009-03-10 2017-03-27 Baylor Res Inst ANTIGEN PRESENTING CELL-TARGETED VACCINES
CN102741295A (zh) * 2009-03-10 2012-10-17 贝勒研究院 靶向抗原呈递细胞的抗病毒疫苗
TWI508976B (zh) * 2009-04-21 2015-11-21 Univ Rockefeller 對β－類澱粉蛋白之基原纖維形式具專一性之抗體

Also Published As

Publication number Publication date
MY159398A (en) 2016-12-30
HUE036737T2 (hu) 2018-07-30
RS54122B1 (en) 2015-12-31
UY32633A (es) 2010-12-31
CY1120413T1 (el) 2019-07-10
JP2012526541A (ja) 2012-11-01
EP2430049B1 (fr) 2015-04-15
US10112991B2 (en) 2018-10-30
BRPI1012853B1 (pt) 2021-08-24
TWI583791B (zh) 2017-05-21
IL216237A0 (en) 2012-01-31
US20190119365A1 (en) 2019-04-25
IL216237B (en) 2018-05-31
HRP20180516T1 (hr) 2018-05-04
AU2010247215B2 (en) 2015-08-20
HK1167152A1 (en) 2012-11-23
EP2977385B1 (fr) 2017-12-27
EP3050898A1 (fr) 2016-08-03
KR101783058B1 (ko) 2017-09-28
TW201641690A (zh) 2016-12-01
UA107574C2 (ru) 2015-01-26
US20120177639A1 (en) 2012-07-12
DK2430049T3 (en) 2015-07-20
MA33350B1 (fr) 2012-06-01
WO2010130946A1 (fr) 2010-11-18
CY1116842T1 (el) 2017-03-15
CR20110585A (es) 2011-12-07
FR2945538B1 (fr) 2014-12-26
EP2430049A1 (fr) 2012-03-21
CL2011002831A1 (es) 2012-05-11
KR20120096950A (ko) 2012-08-31
PL2430049T3 (pl) 2015-09-30
PT2430049E (pt) 2015-09-01
CO6460745A2 (es) 2012-06-15
HRP20181985T1 (hr) 2019-01-25
SG176155A1 (en) 2011-12-29
MX2011012060A (es) 2012-04-30
FR2945538A1 (fr) 2010-11-19
CA2761665A1 (fr) 2010-11-18
DK2977385T3 (en) 2018-04-16
SI2977385T1 (en) 2018-05-31
HRP20150776T1 (hr) 2015-08-28
AR076670A1 (es) 2011-06-29
US20160368977A1 (en) 2016-12-22
US8614299B2 (en) 2013-12-24
PE20120906A1 (es) 2012-08-08
EP2977385A1 (fr) 2016-01-27
EA028357B1 (ru) 2017-11-30
TN2011000571A1 (fr) 2013-05-24
NZ596540A (en) 2013-05-31
GT201100283A (es) 2013-11-07
ZA201108301B (en) 2013-01-30
CN102459336A (zh) 2012-05-16
JP6310895B2 (ja) 2018-04-11
BRPI1012853A2 (pt) 2018-06-19
US9382312B2 (en) 2016-07-05
CN102459336B (zh) 2016-04-20
SV2011004058A (es) 2012-06-06
ES2542757T3 (es) 2015-08-11
SI2430049T1 (sl) 2015-08-31
JP2016028591A (ja) 2016-03-03
TWI542360B (zh) 2016-07-21
ECSP11011452A (es) 2011-12-30
PL2977385T3 (pl) 2018-06-29
PT2977385T (pt) 2018-04-03
NI201100195A (es) 2012-02-01
AU2010247215A1 (en) 2011-12-15
EP3050898B1 (fr) 2018-08-15
ES2664409T3 (es) 2018-04-19
US20140105890A1 (en) 2014-04-17
TW201100102A (en) 2011-01-01
LT2977385T (lt) 2018-04-10

Similar Documents

Publication Publication Date Title
EA201171388A1 (ru) Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
CY1122278T1 (el) Αντι il-36r αντισωματα
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201270722A1 (ru) Формы рифаксимина и их применение
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
MX2019015602A (es) Anticuerpos contra el beta-amiloide.
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
CR20120453A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfp)
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
WO2012021475A3 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
EA201300130A1 (ru) Способ лечения болезни альцгеймера
EA201591133A1 (ru) СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19
EA201390467A1 (ru) Композиции антител и способы применения
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
TH128722B (th) ฮิวมาไนซ์แอนติบอดีที่จำเพาะต่อรูปโปรโตไฟบริลลาร์ของบีตา-อมัยลอยด์เพพไทด์
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
TH0901001837A (th) การใช้เอโพไธโลน D ในการรักษาโรคที่เกี่ยวโยงกับ Tau ซึ่งรวมถึงโรคอัลไซเมอร์

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KG TJ TM